All Resolutions Passed at Ping An Biomedical AGM, Clearing Path for Restructured Share Capital
MWN-AI** Summary
Ping An Biomedical Co., Ltd (NASDAQ: PASW) announced the successful passing of all five resolutions during its Annual General Meeting (AGM) held on March 18, 2026. This pivotal meeting enabled a comprehensive restructuring of the company’s share capital, significantly enhancing its corporate governance and financial strategy.
One of the key resolutions authorized substantial changes to the authorized share capital of the company. The capital will expand from US$50,000 to US$312,500, allowing for up to 5,000,000,000 ordinary shares. A new Class B share series was introduced, consisting of 100,000,000 high-vote shares, which will possess 100 votes each, ensuring substantial voting power is concentrated among select shareholders.
Moreover, shareholders approved a targeted share exchange with INSPIRETECH LTD, wherein the company will repurchase 12,250,000 Class A shares while issuing an equivalent number of Class B shares. This strategic move is expected to maintain the overall shareholding while enabling INSPIRETECH to gain high-vote shares.
The AGM also saw the approval of a share consolidation process, whereby every 1,000 existing Class A and Class B shares will be consolidated into one share of their respective classes. This measure aims to streamline the share structure and potentially enhance share value.
Finally, the resolutions included adopting the second amended and restated memorandum and articles of association, reflecting these significant changes. Following the AGM, the board has the authority to implement these resolutions effectively.
Ping An Biomedical is recognized for its innovation in healthcare and biomedical technology, positioning itself as a leader within the apparel industry through its one-stop supply chain management services. The successful AGM sets a strong foundation for the company’s future growth and strategic objectives.
MWN-AI** Analysis
Following the recent Annual General Meeting (AGM) of Ping An Biomedical Co., Ltd (NASDAQ: PASW), the approval of all five resolutions marks a significant turning point for the company, especially in its capital structure and shareholder dynamics. The restructuring involves an overhaul to implement Class B shares with enhanced voting power, which strategically increases control for certain stakeholders while maintaining existing ownership levels.
The approved share capital restructuring raises Ping An Bio's authorized capital significantly, expanding its pool of shares to drive potential investment and liquidity. This move enhances the ability to attract strategic investors and positions the company to leverage growth opportunities in the biomedical sector. The introduction of high-vote Class B shares indicates a clear intention to concentrate voting control while simultaneously solidifying the confidence of significant shareholders, particularly INSPIRETECH LTD, by allowing a targeted exchange and repurchase of shares.
Furthermore, the strategic share consolidation—where every 1,000 shares consolidate into one—will likely enhance the share performance by reducing the total number of shares outstanding, thereby increasing earnings per share (EPS) and potentially elevating the company's stock price.
Investors should closely monitor the implications of these changes, particularly the effects on share valuation and market perception. The consolidation could lead to a favorable liquidity position and a stronger share value trajectory as market analysts often perceive such structural adjustments positively, signaling a company poised for robust growth.
In conclusion, the AGM resolutions position Ping An Bio for strategic advancements in its operational framework, presenting a compelling case for investment. Investors are encouraged to assess their positions carefully and remain vigilant for any signals from market performance following the implementation of these resolutions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
HONG KONG, March 19, 2026 (GLOBE NEWSWIRE) -- Ping An Biomedical Co., Ltd (NASDAQ: PASW) (hereinafter referred to as “Ping An Bio”) announced that shareholders have approved all five resolutions at the company’s 2026 Annual General Meeting, providing full authorization for an overhaul of its share capital structure, the introduction of high?vote Class B shares, a targeted share exchange with a major shareholder, and a large?scale share consolidation.
Authorised Share Capital Changes
Shareholders resolved by an ordinary resolution that, the Company authorised share capital of the Company be amended in the manner and sequence set out below with immediate effect (collectively, the Authorised Share Capital Changes):
(a) increasing the authorised share capital US$50,000 divided into 800,000,000 ordinary shares of a nominal or par value of US$0.0000625 each to US$312,500 divided into 5,000,000,000 ordinary shares of a par value US$0.0000625 each, by the addition of 4,200,000,000 ordinary shares of a par value US$0.0000625 each;
(b) re-designating and re-classifying 4,900,000,000 authorised ordinary shares of a par value US$0.0000625 each (including all existing issued ordinary shares) as 4,900,000,000 class A ordinary shares of par value US$0.0000625 each (the Class A Shares), where the rights of the existing ordinary shares shall be the same as the Class A Shares;
(c) cancelling 100,000,000 authorised but unissued ordinary shares of a par value US$0.0000625 each and create a new share class of 100,000,000 class B ordinary shares of par value US$0.0000625 each (the Class B Shares), which will be entitled to one hundred (100) votes per share,
such that the authorised share capital of the Company shall become US$312,500 divided into 4,900,000,000 class A ordinary shares of a par value US$0.0000625 each and 100,000,000 class B ordinary shares of a par value US$0.0000625 each.
Adoption of Second Amended and Restated Memorandum and Articles of Association
Shareholders resolved by a special resolution that the second amended and restated memorandum and articles of association of the Company, in the substantial form attached to the notice of annual general meeting and the proxy statement as Appendix 1 (the Second Amended MAA), be adopted in substitution for and to the exclusion of the existing memorandum and articles of association of the Company in its entirety with effect upon the Authorised Share Capital Changes taking effect.
Share repurchase and issuance
Shareholders resolved by an ordinary resolution that, subject to the Authorised Share Capital Changes and Second Amended MAA taking effect and the Company’s receipt of the consent to repurchase and application for shares duly executed by INSPIRETECH LTD (“INSPIRETECH”), the Board be and is hereby authorised to repurchase 12,250,000 Class A Shares from INSPIRETECH, all of which are fully paid shares, in consideration of and out of the proceeds of the Company’s new issuance of 12,250,000 Class B Shares to INSPIRETECH. The arrangement effectively converts part of INSPIRETECH’s holding into high?vote shares while keeping the number of shares held by that shareholder unchanged.
Share consolidation
Shareholders resolved by an ordinary resolution that, following the Authorised Share Capital Changes, and conditional upon the approval of the Board, with effect on a date within one (1) calendar year after the conclusion of the Meeting to be determined by the Board:
(d) every one thousand (1,000) then issued and unissued Class A Shares, or such lesser whole share amount of not being less than two (2) as the Board may determine in its sole discretion, be consolidated into one (1) class A ordinary share (the Consolidated Class A Share(s)), where such Consolidated Class A Shares shall rank pari passu in all respect with each other and have the same rights and are subject to the same restrictions (save as to par value) as the existing Class A Shares as set out in the Second Amended MAA;
(e) every one thousand (1,000) then issued and unissued Class B Shares, or such lesser whole share amount of not being less than two (2) as the Board may determine in its sole discretion, be consolidated into one (1) class B ordinary share (the Consolidated Class B Share(s)), where such Consolidated Class B Shares shall rank pari passu in all respect with each other and have the same rights and are subject to the same restrictions (save as to par value) as the existing Class B Shares as set out in the Second Amended MAA;
(collectively, the Share Consolidation)
(f) all fractional entitlements to the issued Consolidated Class A Shares and Consolidated Class B Shares resulting from the Share Consolidation will not be issued to the shareholders of the Company and instead, any fractional shares that would have resulted from the Share Consolidation will be rounded up to the next whole number; and
(g) the Board be authorised and directed to do all such acts and things as it may consider necessary or desirable for the purpose of effectuating the Share Consolidation, including determining the definitive ratio and the effective date of the Share Consolidation and any other changes to the Company’s authorised share capital in connection with and as necessary to effect the Share Consolidation.
Amendment of Memorandum and Articles of Association reflecting Share Consolidation
Shareholders resolved by a special resolution that subject to and immediately following the Share Consolidation being effected, the relevant provisions of the memorandum and articles of association of the Company then in effect be amended to reflect the Share Consolidation.
The AGM was held on 18 March 2026, with shareholders of record as of 3 March 2026 entitled to vote in person or by proxy. Each ordinary share carried one vote at the meeting, and all five resolutions received the requisite majority of votes cast, in line with the board of directors’ unanimous recommendation.
About Ping An Biomedical Co., Ltd
Ping An Biomedical Co., Ltd. is a one-stop SCM service provider in the apparel industry. It is also a forward-thinking company dedicated to delivering innovative solutions in healthcare and biomedical technology.
For more information, please contact:Ping An Biomedical Co., Ltd.Email: corpsec@pingan365.vipCelestia Investor RelationsEmail: investors@celestiair.com
FAQ**
How will the introduction of high-vote Class B shares in Ping An Biomedical Co Ltd Ord Shs PASW impact shareholder voting power and control within the company?
What are the expected benefits of the share consolidation for existing shareholders of Ping An Biomedical Co Ltd Ord Shs PASW in terms of share value and market perception?
How does the targeted share exchange with INSPIRETECH LTD relate to the overall strategy and future growth plans of Ping An Biomedical Co Ltd Ord Shs PASW?
What implications will the amendment of the memorandum and articles of association have for the governance structure of Ping An Biomedical Co Ltd Ord Shs PASW after the AGM resolutions?
**MWN-AI FAQ is based on asking OpenAI questions about Ping An Biomedical Co Ltd Ord Shs (NASDAQ: PASW).
NASDAQ: PASW
PASW Trading
-4.8% G/L:
$0.1349 Last:
87,861 Volume:
$0.1416 Open:
